{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:25:28Z","timestamp":1793741128910,"version":"4.6.1"},"reference-count":35,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Zhejiang Provincial TCM Academic Inheritance and Specialty Construction Project","award":["No.2A11543"],"award-info":[{"award-number":["No.2A11543"]}]},{"name":"The 13th Five-Year Plan Key Discipline Construction Program of Traditional Chinese Medicine (Integrated Traditional Chinese and Western Medicine) in Zhejiang Province","award":["No.2017-XK-A09"],"award-info":[{"award-number":["No.2017-XK-A09"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Mens Health"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>This review employs bibliometric methods to map the evolving landscape of prostate cancer endocrine therapy research over the past 15\u2009years. Through analysis of 961 articles from the Web of Science Core Collection, we identified key trends in therapeutic innovation and clinical translation. The United States emerged as the dominant contributor (34.96% of publications), with Harvard University and the University of California System leading institutional output. Three paradigm shifts emerged: early stage research focused on optimizing androgen deprivation therapy (ADT) efficacy (2008\u20132013), followed by castration-resistant prostate cancer (CRPC) drug development (2014\u20132016), and recent emphasis on combination therapies and molecular targeting (2017\u20132023). The top 50 most cited papers confirmed that keyword clusters directly corresponded to pivotal trials, including TAMPEDE (NCT00268476) and PROSPER (NCT02003924). The translational science spectrum model revealed that 68% of current clinical applications originated from basic research on androgen receptor variants. Emerging frontiers include prostate-specific membrane antigen-targeted radioligand therapy and immunotherapy-ADT synergies. This synthesis provides clinicians with an evidence-based roadmap to navigate therapeutic advancements while highlighting the critical need for international collaboration in addressing persistent challenges such as treatment resistance.<\/jats:p>","DOI":"10.1177\/15579883251346819","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T06:51:27Z","timestamp":1750402287000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008\u20132023)"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4469-3199","authenticated-orcid":false,"given":"Longjun","family":"Huang","sequence":"first","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0586-1579","authenticated-orcid":false,"given":"Wenjuan","family":"He","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4217-8053","authenticated-orcid":false,"given":"Yong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","unstructured":"An R. Schmid R. Klausing A. Robering J. W. Weber M. B\u00e4uerle T. Detsch R. Boccaccini A. R. Horch R. E. Boos A. M. Weigand A. (2018). Proangiogenic effects of tumor cells on endothelial progenitor cells vary with tumor type in an in vitro and in vivo rat model. FASEB Journal 32(10) 5587\u20135601. https:\/\/doi.org\/10.1096\/fj.201800135RR","DOI":"10.1096\/fj.201800135RR"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Attard G. Murphy L. Clarke N. W. Cross W. Jones R. J. Parker C. C. Gillessen S. Cook A. Brawley C. Amos C. L. Atako N. Pugh C. Buckner M. Chowdhury S. Malik Z. Russell J. M. Gilson C. Rush H. Bowen J. \u2026 Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. (2022). Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 399(10323) 447\u2013460. https:\/\/doi.org\/10.1016\/s0140-6736(21)02437-5","DOI":"10.1016\/S0140-6736(21)02437-5"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Beer T. M. Armstrong A. J. Rathkopf D. Loriot Y. Sternberg C. N. Higano C. S. Iversen P. Evans C. P. Kim C. S. Kimura G. Miller K. Saad F. Bjartell A. S. Borre M. Mulders P. Tammela T. L. Parli T. Sari S. van Os S. \u2026 Tombal B. (2017). Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: Extended analysis of the phase 3 PREVAIL study. European Urology 71(2) 151\u2013154. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.032","DOI":"10.1016\/j.eururo.2016.07.032"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Chaput G. Sumar N. (2022). Endocrine therapies for breast and prostate cancers: Essentials for primary care. Canadian Family Physician 68(4) 271\u2013276. https:\/\/doi.org\/10.46747\/cfp.6804271","DOI":"10.46747\/cfp.6804271"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Chen K. Jiang K. Tang L. Chen X. Hu J. Sun F. (2021). Analysis of clinical trials on therapies for prostate cancer in Mainland China and globally from 2010 to 2020. Frontiers in Oncology 11 647110. https:\/\/doi.org\/10.3389\/fonc.2021.647110","DOI":"10.3389\/fonc.2021.647110"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Cornford P. van den Bergh R. C. N. Briers E. Van den Broeck T. Brunckhorst O. Darraugh J. Eberli D. De Meerleer G. De Santis M. Farofi A. Gandaglia G. Gillessen S. Grivas N. Henry A. M. Lardas M. van Leenders G. J. L. H. Liew M. Espinos E. L. Olderburg J. \u2026 Tilki D. (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening diagnosis and local treatment with curative intent. European Urology 86(2) 148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Croucher P. I. McDonald M. M. Martin T. J. (2016). Bone metastasis: The importance of the neighbourhood. Nature Reviews. Cancer 16(6) 373\u2013386. https:\/\/doi.org\/10.1038\/nrc.2016.44","DOI":"10.1038\/nrc.2016.44"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Davis I. D. Martin A. J. Stockler M. R. Begbie S. Chi K. N. Chowdhury S. Coskinas X. Frydenberg M. Hague W. E. Horvath L. G. Joshua A. M. Lawrence N. J. Marx G. McCaffrey J. McDermott R. McJannett M. North S. A. Parnis F. Parulekar W. \u2026 ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. The Natural England Journal of Medicine 381(2) 121\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1903835","DOI":"10.1056\/NEJMoa1903835"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Ellegaard O. Wallin J. A. (2015). The bibliometric analysis of scholarly production: How great is the impact? Scientometrics 105(3) 1809\u20131831. https:\/\/doi.org\/10.1007\/s11192-015-1645-z","DOI":"10.1007\/s11192-015-1645-z"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Emmett L. Subramaniam S. Crumbaker M. Nguyen A. Joshua A. M. Weickhardt A. Lee S. T. Ng S. Francis R. J. Goh J. C. Pattison D. A. Tan T. H. Kirkwood I. D. Gedye C. Rutherford N. K. Sandhu S. Kumar A. R. Pook D. Ramdave S. \u2026 ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. (2024). [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): An open-label multicentre randomised phase 2 trial. The Lancet Oncology 25(5) 563\u2013571. https:\/\/doi.org\/10.1016\/s1470-2045(24)00135-9","DOI":"10.1016\/S1470-2045(24)00135-9"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Fega K. R. Abel G. A. Motyckova G. Sherman A. E. DeAngelo D. J. Steensma D. P. Galinsky I. Wadleigh M. Stone R. M. Driver J. A. (2015). Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. Journal of Geriatric Oncology 6(4) 288\u2013298. https:\/\/doi.org\/10.1016\/j.jgo.2015.05.003","DOI":"10.1016\/j.jgo.2015.05.003"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Fizazi K. Scher H. I. Molina A. Logothetis C. J. Chi K. N. Jones R. J. Staffurth J. N. North S. Vogelzang N. J. Saad F. Mainwaring P. Harland S. Goodman Jr. O. B. Sternberg C. N. Li J. H. Kheoh T. Haqq C. M. \u2026 COU-AA-301 Investigators. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised double-blind placebo-controlled phase 3 study. The Lancet Oncology 13(10) 983\u2013992. https:\/\/doi.org\/10.1016\/s1470-2045(12)70379-0","DOI":"10.1016\/S1470-2045(12)70379-0"},{"issue":"7","key":"e_1_3_3_14_1","first-page":"19","article-title":"Current status of endocrine therapy for prostate cancer","volume":"1","author":"Garnick M. B.","year":"1987","unstructured":"Garnick M. B. (1987). Current status of endocrine therapy for prostate cancer. Oncology (Williston Park), 1(7), 19\u201325, 30\u201311, 34.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Giraudet A. L. Kryza D. Hofman M. Moreau A. Fizazi K. Flechon A. Hicks R. J. Tran B. (2021). PSMA targeting in metastatic castration-resistant prostate cancer: Where are we and where are we going? Therapeutic Advances in Medical Oncology 13 17588359211053898. https:\/\/doi.org\/10.1177\/17588359211053898","DOI":"10.1177\/17588359211053898"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Gudenkauf L. M. Gray S. Gonzalez B. D. Sachdeva A. Autio K. (2024). Balancing hormone therapy: Mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management. American Society of Clinical Oncology Educational Book 44(3) e433126. https:\/\/doi.org\/10.1200\/edbk_433126","DOI":"10.1200\/EDBK_433126"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Hou\u00e9d\u00e9 N. Hebert K. (2024). Combining enzalutamide and [(177)Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. The Lancet Oncology 25(5) 531\u2013533. https:\/\/doi.org\/10.1016\/s1470-2045(24)00179-7","DOI":"10.1016\/S1470-2045(24)00179-7"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Kim T. J. Koo K. C. (2020). Pathophysiology of bone loss in patients with prostate cancer receiving androgen-deprivation therapy and lifestyle modifications for the management of bone health: A comprehensive review. Cancers (Basel) 12(6). 1529. https:\/\/doi.org\/10.3390\/cancers12061529","DOI":"10.3390\/cancers12061529"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Knuuttila M. Yatkin E. Kallio J. Savolainen S. Laajala T. D. Aittokallio T. Oksala R. Hakkinen M. Keski-Rahkonen P. Auriola S. Poutanen M. M\u00e4kel\u00e4 S. (2014). Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. The American Journal of Pathology 184(8) 2163\u20132173. https:\/\/doi.org\/10.1016\/j.ajpath.2014.04.010","DOI":"10.1016\/j.ajpath.2014.04.010"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Mateo J. Fizazi K. Gillessen S. Heidenreich A. Perez-Lopez R. Oyen W. J. G. Shore N. Smith M. Sweeney C. Tombal B. Tomlins S. A. de Bono J. S. (2019). Managing nonmetastatic castration-resistant prostate cancer. European Urology 75(2) 285\u2013293. https:\/\/doi.org\/10.1016\/j.eururo.2018.07.035","DOI":"10.1016\/j.eururo.2018.07.035"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"McCutcheon S. B. (2013). Enzalutamide: A new agent for the prostate cancer treatment armamentarium. Jouenal of the Advanced Practitioner in Oncol 4(3) 182\u2013185. https:\/\/doi.org\/10.6004\/jadpro.2013.4.3.7","DOI":"10.6004\/jadpro.2013.4.3.7"},{"key":"e_1_3_3_22_1","unstructured":"Namiki M. Ueno S. Kitagawa Y. (2012). Role of hormonal therapy for prostate cancer: Perspective from Japanese experiences. Translational Andrology and Urology 1(3) 160\u2013172. https:\/\/doi.org\/10.3978\/j.issn.2223-4683.2012.07.03"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Pineda-Moncus\u00ed M. Servitja S. Casamayor G. Cos M. L. Rial A. Rodriguez-Morera J. Tusquets I. Diez-Perez A. Garcia-Giralt N. Nogu\u00e9s X. (2018). Bone health evaluation one year after aromatase inhibitors completion. Bone 117 54\u201359. https:\/\/doi.org\/10.1016\/j.bone.2018.09.010","DOI":"10.1016\/j.bone.2018.09.010"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Powles T. Yuen K. C. Gillessen S. Kadel E. E.3rd Rathkopf D. Matsubara N. Drake C. G. Fizazi K. Piulats J. M. Wysocki P. J. Buchschacher Jr. G. L. Alekseev B. Mellado B. Karaszewska B. Doss J. F. Rasuo G. Datye A. Mariathasan S. Williams P \u2026 Sweeney C. J. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: A randomized phase 3 trial. Nature Medicine 28(1) 144\u2013153. https:\/\/doi.org\/10.1038\/s41591-021-01600-6","DOI":"10.1038\/s41591-021-01600-6"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Rajwa P. Quhal F. Tsaur I. (2023). Current management and future treatment strategies for patients with metastatic hormone-sensitive prostate cancer. World Journal of Urology 41(8) 2005\u20132006. https:\/\/doi.org\/10.1007\/s00345-023-04542-5","DOI":"10.1007\/s00345-023-04542-5"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Reiss A. B. Gulkarov S. Pinkhasov A. Sheehan K. M. Srivastava A. De Leon J. Katz A. E. (2023). Androgen deprivation therapy for prostate cancer: Focus on cognitive function and mood. Medicina (Kaunas) 60(1). https:\/\/doi.org\/10.3390\/medicina60010077","DOI":"10.3390\/medicina60010077"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","unstructured":"Samuels J. Bienvenu O. J. Krasnow J. Wang Y. Grados M. A. Cullen B. Goes F. S. Maher B. Greenberg B. D. McLaughlin N. C. Rasmussen S. A. Fyer A. J. Knowles J. A. Nestadt P. McCracken J. T. Piacentini J. Geller D. Pauls D. L. Stewart S. E. \u2026 Nestadt G. (2017). An investigation of doubt in obsessive-compulsive disorder. Comprehensive Psychiatry 75 117\u2013124. https:\/\/doi.org\/10.1016\/j.comppsych.2017.03.004","DOI":"10.1016\/j.comppsych.2017.03.004"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"Sartor O. de Bono J. Chi K. N. Fizazi K. Herrmann K. Rahbar K. Tagawa S. T. Nordquist L. T. Vaishampayan N. El-Haddad G. Park C. H. Beer T. M. Armour A. P\u00e9rez-Contreras W. J. DeSilvio M. Kpamegan E. Gericke G. Messmann R. A. Morris M. J. \u2026 VISION Investigators. (2021). Lutetium-177-PSMA-617 for Metastatic castration-resistant prostate cancer. The New England Journal of Medicine 385(12) 1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Sheehan B. Guo C. Neeb A. Paschalis A. Sandhu S. de Bono J. S. (2022). Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications. European Urology Focus 8(5) 1157\u20131168. https:\/\/doi.org\/10.1016\/j.euf.2021.06.006","DOI":"10.1016\/j.euf.2021.06.006"},{"key":"e_1_3_3_30_1","doi-asserted-by":"crossref","unstructured":"Shelley M. D. Kumar S. Wilt T. Staffurth J. Coles B. Mason M. D. (2009). A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treatment Reviews 35(1) 9\u201317. https:\/\/doi.org\/10.1016\/j.ctrv.2008.08.002","DOI":"10.1016\/j.ctrv.2008.08.002"},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"Smith M. R. Egerdie B. Hern\u00e1ndez Toriz N. Feldman R. Tammela T. L. Saad F. Heracek J. Szwedowski M. Ke C. Kupic A. Leder B. Z. Goessl C. & Denosumab HALT Prostate Canser Study Group. (2009). Denosumab in men receiving androgen-deprivation therapy for prostate cancer. The New England Journal of Medicine 361(8) 745\u2013755. https:\/\/doi.org\/10.1056\/NEJMoa0809003","DOI":"10.1056\/NEJMoa0809003"},{"key":"e_1_3_3_32_1","doi-asserted-by":"crossref","unstructured":"Sternberg C. N. Fizazi K. Saad F. Shore N. D. De Giorgi U. Penson D. F. Ferreira U. Efstathiou E. Madziarska K. Kolinsky M. P. Cubero D. I. G. Noerby B. Zohren F. Lin X. Modelska K. Sugg J. Steinberg J. Hussain M. PROSPER Investigators. (2020). Enzalutamide and survival in nonmetastatic castration-resistant prostate cancer. The New England Journal of Medicine 382(23) 2197\u20132206. https:\/\/doi.org\/10.1056\/NEJMoa2003892","DOI":"10.1056\/NEJMoa2003892"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","unstructured":"Sung H. Ferlay J. Siegel R. L. Laversanne M. Soerjomataram I. Jemal A. Bray F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians 71(3) 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_3_34_1","doi-asserted-by":"crossref","unstructured":"Turco F. Di Prima L. Pisano C. Poletto S. De Filippis M. Crespi V. Farinea G. Cani M. Calabrese M. Saporita I. Di Stefano R. F. Tucci M. Buttigliero C. (2023). How to improve the quality of life of patients with prostate cancer treated with hormone therapy? Research and Reports in Urology 15 9\u201326. https:\/\/doi.org\/10.2147\/rru.S350793","DOI":"10.2147\/RRU.S350793"},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"Vogel V. G. (2011). Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women. Breast Cancer (Dove Med Press) 3 127\u2013137. https:\/\/doi.org\/10.2147\/bctt.S11288","DOI":"10.2147\/BCTT.S11288"},{"key":"e_1_3_3_36_1","doi-asserted-by":"crossref","unstructured":"Wadia R. Petrylak D. P. (2014). New developments in the treatment of castration resistant prostate cancer. Asian Journal of Andrology 16(4) 555\u2013560. https:\/\/doi.org\/10.4103\/1008-682x.127824","DOI":"10.4103\/1008-682X.127824"}],"container-title":["American Journal of Men's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15579883251346819","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15579883251346819","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15579883251346819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:28:14Z","timestamp":1777505294000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15579883251346819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/15579883251346819"],"URL":"https:\/\/doi.org\/10.1177\/15579883251346819","relation":{},"ISSN":["1557-9883","1557-9891"],"issn-type":[{"value":"1557-9883","type":"print"},{"value":"1557-9891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"article-number":"15579883251346819"}}